Jinxin Fertility Group Ltd (1951) Fair Value & Analysis

Healthcare · HK · Market cap HK$5.1B

Below-average quality, and screening another 37% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (HK$2.00). The favourable scenario is already priced in.
• Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The model range is unusually wide (HK$0.6120 to HK$2.00). The outcome hinges heavily on assumptions, so read the point estimate with caution.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range HK$1.93 – HK$21.20 · fair‑value band HK$0.6120 – HK$2.00 · the HK$2.08 price screens above the HK$1.31 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Jinxin Fertility Group Ltd (1951) currently trades at HK$2.08, while our model-based Fair Value estimate is HK$1.31, implying the stock looks roughly 36.8% overvalued today. The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Jinxin Fertility Group Ltd generated revenue of HK$2.6B at a net margin of -36.9%. Revenue declined 0.5% year over year. It earns a return on equity of -10.1%. Net debt stands at HK$2.1B. Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$0.6120 (bear case) to HK$2.00 (bull case); at HK$2.08, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 43% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -37%, 1951 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Asset-Based (HK$2.40) versus Earnings-Based (HK$0.3700). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and internationally.

Full company description

Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and internationally. The company provides two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. It also related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS. In addition, the company offers management services; obstetrics, gynecology, urology, internal medicine, and pediatrics medical services; ambulatory surgery center facilities services; and ancillary medical services. Further, it provides pre-implantation genetic screening testing, management consultancy, postpartum and rehabilitation care, maternal-child nursing, and other hospital- derived services. Additionally, the company is involved in property investment, and real estate development and operation activities; sale of medicines, consumables, and equipment; research and development of IVF related projects, including scientific research and related commercialization; and operates restaurant. Jinxin Fertility Group Limited was founded in 1951 and is headquartered in Chengdu, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Jinxin Fertility Group Ltd reported revenue of HK$2.6B in FY2025 versus HK$1.8B in FY2021, a compound +8.8%/yr. Reported net income was −HK$951M in FY2025.

1951 screens 37% overvalued. Compare with HCA Healthcare, Inc →

Peer Group

Medical Care Facilities · 266 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.